ITM Isotope Technologies Munich SE in the news
Radiopharmaceuticals for cancer treatment
Tamtam found 20 recent articles about ITM Isotope Technologies Munich SE.
- ITM and Lumara Bio to Announce New Data for ¹⁷⁷Lu-edotreotide (ITM-11) and Ga-DPI-4452 at EANM 2026
ITM and Lumara Bio are set to announce new data for radiopharmaceuticals ITM-11 and Ga-DPI-4452 at the European Association of Nuclear Medicine Congress.
- Sidley Represents Telix Pharmaceuticals in Its US$1.65 Billion Merger With ITM
Telix Pharmaceuticals is acquiring ITM Isotope Technologies Munich SE for US$1.65 billion to expand its radiopharmaceutical capabilities.
- ITM and Lumara Bio Announce Real-World Re-treatment Data and Dosimetry Results from COMPETE for ¹⁷⁷Luedotreotide (ITM-11) in GEP-NETs at ASTRO 2026
ITM and Lumara Bio presented real-world re-treatment data and dosimetry results for 177Lu-edotreotide in GEP-NETs at ASTRO 2026, showing improved survival and favorable dosing.
- ITM and Lumara Bio Announce Real-World Re-treatment Data and Dosimetry Results from COMPETE for ¹⁷⁷Luedotreotide (ITM-11) in GEP-NETs at ASTRO 2026
ITM and Lumara Bio announced positive real-world re-treatment data and favorable dosimetry results for 177Lu-edotreotide (ITM-11) in GEP-NETs at ASTRO 2026.
- ITM and Lumara Bio Announce Upcoming Dosimetry and Re-treatment Data Presentations on ¹⁷⁷Lu-edotreotide at ASTRO 2026
ITM and Lumara Bio will present new dosimetry and re-treatment data for their radiotherapeutic drug, 177Lu-edotreotide, for neuroendocrine tumors at the 2026 ASTRO Annual Meeting.
- Australia's Telix Pharma signs strategic agreement of $1.65 B to merge with ITM Isotope Technologies
Telix Pharmaceuticals will merge with ITM Isotope Technologies Munich SE for $1.65 billion to strengthen its radiopharmaceutical leadership and expand into new therapeutic markets.
- Telix Pharma to Buy ITM Isotope for $1.65 Billion in Radiopharma Push
Telix Pharmaceuticals will acquire ITM Isotope Technologies Munich SE for $1.65 billion to boost its radiopharmaceutical capabilities and pipeline, including the advanced therapeutic candidate ITM-11.
- Herbert Smith Freehills Kramer advises Telix Pharmaceuticals Limited on its transformational merger with ITM Isotope Technologies Munich SE
Herbert Smith Freehills Kramer advised Telix Pharmaceuticals Limited on its US$1.65 billion merger with ITM Isotope Technologies Munich SE to create a vertically integrated radiopharmaceutical company.
- Transcript : Telix Pharmaceuticals Limited, ITM Isotope Technologies Munich SE - M&A Call
Telix Pharmaceuticals Limited and ITM Isotope Technologies Munich SE are holding a call to discuss their M&A announcement.
- ITM and Lumara Bio Announce Upcoming Dosimetry and Re-treatment Data Presentations on ¹⁷⁷Lu-edotreotide at ASTRO 2026
ITM and Lumara Bio will present new dosimetry and re-treatment data for 177Lu-edotreotide (ITM-11) in neuroendocrine tumors at ASTRO 2026.
- Latham & Watkins berät ITM bei Fusion mit Telix im Wert von bis zu 2,35 Mrd. US-Dollar
Telix Pharmaceuticals will merge with ITM Isotope Technologies Munich SE in a deal advised by Latham & Watkins.
- Telix Pharmaceuticals Says To Acquire ITM Isotope Technologies Munich SE for $1.65 billion
Telix Pharmaceuticals will acquire ITM Isotope Technologies Munich SE for $1.65 billion.
- Telix Pharmaceuticals fällt nach milliardenschwerer ITM-Übernahme
Telix Pharmaceuticals' stock dropped following its $1.65 billion acquisition of ITM Isotope Technologies Munich SE, driven by concerns over share dilution and valuation.
- Telix buys ITM for $1.65B in ‘supercritical’ radiopharma M&A
Telix Pharmaceuticals is acquiring ITM Isotope Technologies Munich for $1.65 billion, creating a vertically integrated radiopharmaceutical company with enhanced manufacturing and a broad distribution network.
- Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
Telix and ITM are merging in a US$1.65 billion deal to form a vertically integrated radiopharmaceutical company, combining Telix's pipeline with ITM's radioisotope production and advanced therapeutic candidates.
- Telix (TLX) to Buy Germany’s ITM for up to $2.35 Billion to Lock in its Cancer Isotope Supply
Telix Pharmaceuticals plans to acquire ITM Isotope Technologies Munich for up to $2.35 billion to secure its cancer isotope supply and acquire ITM's lead drug candidate.
- Telix und ITM: Fusion formt Radiopharma-Schwergewicht
Telix Pharmaceuticals and ITM Isotope Technologies Munich are merging to create a vertically integrated radiopharmaceutical company, combining their complementary strengths in diagnostics, therapy development, and radioisotope production.
- Telix Pharmaceuticals to buy isotope maker ITM in deal worth up to $2.35B
Telix Pharmaceuticals will acquire ITM Isotope Technologies Munich SE, a radiopharmaceutical company, for up to $2.35 billion to enhance its medical radioisotope production and cancer treatment portfolio.
- Telix Pharma Bets Up To $2.3B For ITM In Radiopharma Push
Telix Pharmaceuticals plans to acquire ITM Isotope Technologies Munich SE for up to $2.3 billion to expand its radiopharma business.
- Telix Pharma Bets Up To $2.3B For ITM In Radiopharma Push
Telix Pharmaceuticals plans to acquire ITM Isotope Technologies Munich SE for up to $2.3 billion.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like ITM Isotope Technologies Munich SE?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies